Evidence map›Paper›PMID 34638317›Full record

ArticleCancers2021

Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Prostate Biopsy: Diagnostic Accuracy from a Single Center Retrospective Study.

Andrea Fulco, Francesco Chiaradia, Luigi Ascalone, Vincenzo Andracchio, Antonio Greco, Manlio Cappa, Marcello Scarcia, Giuseppe Mario Ludovico, Vincenzo Pagliarulo, Camillo Palmieri and 1 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea FulcoDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.
Francesco ChiaradiaDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.
Luigi AscaloneDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.
Vincenzo AndracchioDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.ORCID 0000-0002-9252-421X
Antonio GrecoDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.
Manlio CappaDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.
Marcello ScarciaDepartment of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", 70021 Acquaviva delle Fonti, Italy.
Giuseppe Mario LudovicoDepartment of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", 70021 Acquaviva delle Fonti, Italy.
Vincenzo PagliaruloDepartment of Urology, Ospedale Vito Fazzi, 73100 Lecce, Italy.
Camillo PalmieriDepartment of Clinical and Experimental Medicine, University Magna Grecia of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-6707-4723
Stefano AlbaDepartment of Urology, Romolo Hospital, 88821 Rocca di Neto, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of prostate biopsy in men with clinical suspicion of prostate cancer has changed in the last few years, especially with the introduction of imaging techniques, to overcome the low efficacy of risk stratification based on PSA levels. Here, we aimed to compare the diagnostic accuracy of multiparametric MRI with fusion ultrasound-guided prostate biopsy and standard biopsy, both performed through the transperineal route. To this end, we retrospectively analyzed 272 patients who underwent combined transperineal targeted and standard biopsy during the same session. The primary outcome was to compare the cancer detection rate between targeted and standard biopsy. The secondary outcome was to evaluate the added value of combined targeted and standard biopsy approach as compared to only targeted or standard biopsy. Results showed that a rate of 16.7% clinically significant tumors (International Society of Urological Pathology (ISUP) grade ≥ 2) would have been lost if only the standard biopsy had been used. The combined targeted and standard biopsy showed an added value of 10.3% and 9.9% in reducing the risk of prostate cancer missing after targeted or standard biopsy alone, respectively. The combined targeted and standard biopsy pathway is recommended to reduce the risk of missing clinically significant prostate cancer.

Indexed as

biopsyimage-guidedmagnetic resonance imagingprostatic neoplasmsultrasonography

Identifiers

PMID34638317
PMCPMC8507636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.